Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
Public ClinicalTrials.gov record NCT00005603. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ALinC 17: Protocol for Patients With Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective for acute lymphoblastic leukemia. PURPOSE: Phase III trial to determine the effectiveness of combination chemotherapy in treating children who have newly diagnosed acute lymphoblastic leukemia.
Study identification
- NCT ID
- NCT00005603
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 276 participants
Conditions and interventions
Conditions
Interventions
- asparaginase Drug
- cyclophosphamide Drug
- cytarabine Drug
- daunorubicin hydrochloride Drug
- dexamethasone Drug
- doxorubicin hydrochloride Drug
- mercaptopurine Drug
- methotrexate Drug
- prednisone Drug
- thioguanine Drug
- vincristine sulfate Drug
Drug
Eligibility (public fields only)
- Age range
- 1 Year to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2000 (Type not available)
- Primary completion
- Sep 2005 (Actual)
- Completion
- Not listed
- Last update posted
- Feb 20, 2014
Started 2000
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital Los Angeles | Los Angeles | California | 90027-0700 | — |
| Lucile Packard Children's Hospital at Stanford | Palo Alto | California | 94304 | — |
| UCSF Comprehensive Cancer Center | San Francisco | California | 94143-0128 | — |
| Children's National Medical Center | Washington D.C. | District of Columbia | 20010-2970 | — |
| Saint Jude Midwest Affiliate | Peoria | Illinois | 61637 | — |
| Indiana University Cancer Center | Indianapolis | Indiana | 46202-5289 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Mayo Clinic Cancer Center | Rochester | Minnesota | 55905 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216-4505 | — |
| Herbert Irving Comprehensive Cancer Center | New York | New York | 10032 | — |
| State University of New York - Upstate Medical University | Syracuse | New York | 13210 | — |
| Albert Einstein Clinical Cancer Center | The Bronx | New York | 10461 | — |
| Children's Hospital Medical Center - Cincinnati | Cincinnati | Ohio | 45229-3039 | — |
| Doernbecher Children's Hospital | Portland | Oregon | 97201-3098 | — |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| Children's Hospital of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | — |
| University of Texas Medical Branch | Galveston | Texas | 77555-0361 | — |
| University of Texas - MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Children's Hospital and Regional Medical Center - Seattle | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00005603, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2014 · Synced Nov 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00005603 live on ClinicalTrials.gov.